170 related articles for article (PubMed ID: 36551721)
1. Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer.
Daido W; Masuda T; Imano N; Matsumoto N; Hamai K; Iwamoto Y; Takayama Y; Ueno S; Sumii M; Shoda H; Ishikawa N; Yamasaki M; Nishimura Y; Kawase S; Shiota N; Awaya Y; Suzuki T; Kitaguchi S; Fujitaka K; Nagata Y; Hattori N
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551721
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Matama G; Zaizen Y; Matsuo N; Murotani K; Tokito T; Hoshino T
Thorac Cancer; 2023 Jan; 14(1):73-80. PubMed ID: 36377039
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of durvalumab consolidation therapy in the management of patients with stage III non-small-cell lung cancer and preexisting interstitial lung disease.
Kawanaka Y; Yasuda Y; Tanizaki J; Iwashima D; Nonagase Y; Uemasu K; Hirayama Y; Ogura M; Ozaki T; Takahashi KI
Respir Investig; 2022 Sep; 60(5):667-673. PubMed ID: 35725721
[TBL] [Abstract][Full Text] [Related]
5. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
Tao H; Li F; Li R; Han X; Hu Y
Ann Palliat Med; 2020 Sep; 9(5):3623-3628. PubMed ID: 32648466
[TBL] [Abstract][Full Text] [Related]
7. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer.
Fukuda K; Katsurada N; Kawa Y; Satouchi M; Kaneshiro K; Matsumoto M; Takamiya R; Hatakeyama Y; Dokuni R; Matsumura K; Katsurada M; Nakata K; Yoshimura S; Tachihara M
Heliyon; 2023 Oct; 9(10):e20463. PubMed ID: 37822623
[TBL] [Abstract][Full Text] [Related]
9. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities.
Kobayashi H; Wakuda K; Naito T; Mamesaya N; Omori S; Ono A; Kenmotsu H; Murakami H; Endo M; Harada H; Gon Y; Takahashi T
Radiat Oncol; 2021 Mar; 16(1):52. PubMed ID: 33731123
[TBL] [Abstract][Full Text] [Related]
11. The detection, assessment and clinical evolution of interstitial lung abnormalities identified through lung cancer screening.
Balata H; Punjabi A; Chaudhuri N; Greaves M; Yorke J; Booton R; Crosbie P; Hayton C
ERJ Open Res; 2023 Jul; 9(3):. PubMed ID: 37143833
[TBL] [Abstract][Full Text] [Related]
12. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis.
Doyle TJ; Dellaripa PF; Batra K; Frits ML; Iannaccone CK; Hatabu H; Nishino M; Weinblatt ME; Ascherman DP; Washko GR; Hunninghake GM; Choi AMK; Shadick NA; Rosas IO
Chest; 2014 Jul; 146(1):41-50. PubMed ID: 24305643
[TBL] [Abstract][Full Text] [Related]
13. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
14. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy.
Li F; Zhou Z; Wu A; Cai Y; Wu H; Chen M; Liang S
Radiat Oncol; 2018 May; 13(1):82. PubMed ID: 29716649
[TBL] [Abstract][Full Text] [Related]
15. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, Risk Factors, and Outcomes of Adult Interstitial Lung Abnormalities: A Systematic Review and Meta-Analysis.
Grant-Orser A; Min B; Elmrayed S; Podolanczuk AJ; Johannson KA
Am J Respir Crit Care Med; 2023 Sep; 208(6):695-708. PubMed ID: 37534937
[No Abstract] [Full Text] [Related]
17. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy.
Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Harada H; Takahashi T
J Cancer; 2018; 9(11):2054-2060. PubMed ID: 29896291
[No Abstract] [Full Text] [Related]
18. Interstitial lung abnormalities and interstitial lung diseases associated with cigarette smoking in a rural cohort undergoing surgical resection.
Sangani RG; Deepak V; Ghio AJ; Forte MJ; Zulfikar R; Patel Z; King A; Alshaikhnassir E; Abbas G; Vos J
BMC Pulm Med; 2022 Apr; 22(1):172. PubMed ID: 35488260
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Nishimura A; Ono A; Wakuda K; Kawabata T; Yabe M; Miyawaki T; Miyawaki E; Kodama H; Nishioka N; Mamesaya N; Kobayashi H; Omori S; Kenmotsu H; Naito T; Murakami H; Harada H; Takahashi T
Invest New Drugs; 2022 Apr; 40(2):403-410. PubMed ID: 34633575
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
